Clinical Observations of Possible Barbiturate Interference With Anticoagulation

MacDonald, Murdo G.; Robinson, Donald S.

doi:10.1001/jama.1968.03140150001001

Cited by 64 publications

(13 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Induction of substrate metabolism, in qualitative terms, is directionally the opposite of inhibition—substrate metabolism and clearance are increased, AUC and steady‐state concentrations are reduced, and the principal concern is reduction in clinical activity or loss of activity altogether (Table , Figure ). The experimental and clinical phenomena of enzyme induction were first described in the 1960s, largely in the context of impairment of coumarin anticoagulant activity by barbiturates …”

Section: Mechanisms Of Drug Interactions: Inhibition and Inductionmentioning

confidence: 99%

Mechanisms and Consequences of Drug‐Drug Interactions

Greenblatt

2017

Clinical Pharm in Drug Dev

View full text Add to dashboard Cite

Medications used to treat human immunodeficiency virus (HIV) and hepatitis C virus (HCV) infections present a special challenge with respect to the management of potential and actual drug-drug interactions (DDIs). The HIV and HCV treatments may interact with each other, and also interact with drugs of abuse and/or with medications used to treat substance abuse. Possible mechanisms of these DDIs generally include induction or inhibition of activity/expression of human cytochromes P450, glucuronosyl transferases, or energy-dependent transport proteins. These DDIs can be complex and time-dependent in nature. Because time and resources available for new drug development are necessarily limited, not all potential DDIs can be evaluated via clinical pharmacokinetic studies in the course of development of HIV, HCV, and substance abuse treatments. Strategies are needed to refine existing in vitro models and screening techniques to allow more efficient targeting of resources to those clinical studies having the highest impact in terms of enhancing medication effectiveness and patient safety.

show abstract

Section: Mechanisms Of Drug Interactions: Inhibition and Inductionmentioning

confidence: 99%

Mechanisms and Consequences of Drug‐Drug Interactions

Greenblatt

2017

Clinical Pharm in Drug Dev

View full text Add to dashboard Cite

show abstract

“…decrease of effectiveness) with oral contraceptives was raised {Conney, 1969). Finally, since phénobarbital (or ethchlorvynol and meproba mate) induces the metabolism of anticoagulants, discontinuation of any of these drugs in the course of anticoagulant treatment may lead to bleeding episodes {MacDonald and Robinson, 1968).…”

Section: Discussionmentioning

confidence: 99%

Drug Interactions in Psychiatry

Ban¹

1978

Int Pharmacopsychiatry

View full text Add to dashboard Cite

Since maintenance therapy with neuroleptics, lithium and tricyclic antidepressants may have to continue over extended periods of time, drug interactions between these psychotherapeutic agents and non-psychotropic treatments have become of practical clinical significance. In this paper some of the more common or important drug interactions between psychotherapeutic and non-psychotherapeutic agents are discussed.

show abstract

“…One result is that the metabolism of other drugs used in the epileptic patient is accelerated, leading to reduced plasma concentrations and therefore therapeutic failure. Examples of drugs which can be affected in this way include oral anticoagulants (MacDonald & Robinson, 1968); doxycycine (Neuvonen & Penttila, 1974) and steroid compounds such as dexamethasone (Brooks, Werk, Ackerman, Sullivan & Thrasher, 1972), vitamin D (Richens & Rowe, 1970;Lancet, 1972) and the contraceptive pill (Laenger & Detering, 1974).…”

Section: Steady-state Plasma Nortriptyline Concentrations In Epileptimentioning

confidence: 99%